Morphosys AG(MOR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MOR Morphosys AG

休市中 05-10 16:00:00 EDT

18.00

+0.13

+0.73%

盘后18.00

+0.000.00%

16:00 EDT

最高18.03	最低17.92	成交量18.78万
今开17.96	昨收17.87	日振幅0.64%
总市值27.12亿	流通市值20.22亿	总股本1.51亿
成交额337.76万	换手率0.17%	流通股本1.12亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"MOR","market":"US","secType":"STK","nameCN":"Morphosys AG","latestPrice":18,"timestamp":1715371200000,"preClose":17.87,"halted":0,"volume":187789,"hourTrading":{"tag":"盘后","latestPrice":18,"preClose":18,"latestTime":"16:00 EDT","volume":626,"amount":11268,"timestamp":1715371201332},"delay":0,"floatShares":112332807,"shares":150650952,"eps":-3.529278,"marketStatus":"休市中","marketStatusCode":7,"change":0.13,"latestTime":"05-10 16:00:00 EDT","open":17.96,"high":18.03,"low":17.915,"amount":3377555.489623,"amplitude":0.006435,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.529278,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1715587200000},"adr":1,"listingDate":1524110400000,"adjPreClose":17.87,"adrRate":0.25,"preHourTrading":{"tag":"盘前","latestPrice":17.96,"preClose":17.87,"latestTime":"09:29 EDT","volume":822,"amount":14763.12,"timestamp":1715347770060},"postHourTrading":{"tag":"盘后","latestPrice":18,"preClose":18,"latestTime":"16:00 EDT","volume":626,"amount":11268,"timestamp":1715371201332},"volumeRatio":0.4724936241976829},"requestUrl":"/m/hq/s/MOR","defaultTab":"news","newsList":[{"id":"2432183683","title":"Morphosys2024财年第一财季实现净利润-3.38亿美元，同比减少609.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432183683","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432183683?lang=zh_cn&edition=full","pubTime":"2024-05-04 00:27","pubTimestamp":1714753632,"startTime":"0","endTime":"0","summary":"3月31日，Morphosys公布财报，公告显示公司2024财年第一财季净利润为-3.38亿美元，同比减少609.04%；其中营业收入为29.89百万美元，同比减少55.29%，每股基本收益为-2.27美元。从资产负债表来看，Morphosys总负债22.61亿美元，其中短期债务6.27百万美元，资产负债比为0.88，流动比率为1.39。机构评级：截至2024年3月31日，当前有7家机构对Morphosys目标价做出预测，其中目标均价为16.39美元，其中最低目标价为10.80美元，最高目标价为18.51美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405040027158b70dc1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405040027158b70dc1c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431124263","title":"大公司日报|万科再发声，管理层将增持！郁亮：股价距要求很远","url":"https://stock-news.laohu8.com/highlight/detail?id=2431124263","media":"腾讯自选股","top":-1,"share":"https://www.laohu8.com/m/news/2431124263?lang=zh_cn&edition=full","pubTime":"2024-04-30 19:07","pubTimestamp":1714475268,"startTime":"0","endTime":"0","summary":"管理层将增持，郁亮：股价距自己要求很远2、华为一季度归母净利润约196.5亿元，同比增长约564%3、特斯拉和百度地图独家深度定制车道级高辅地图4、苹果从谷歌挖走多名AI专家1、万科再发声！4月30日，万科董事会主席郁亮在万科2023年度股东大会上首次发言，对万科股价波动问题予以回应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301848047a57b751&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301848047a57b751&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431947817","title":"Morphosys盘中异动 股价大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431947817","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431947817?lang=zh_cn&edition=full","pubTime":"2024-04-30 01:53","pubTimestamp":1714413225,"startTime":"0","endTime":"0","summary":"北京时间2024年04月30日01时53分，Morphosys股票出现异动，股价急速下挫5.02%。Morphosys股票所在的生物技术行业中，整体涨幅为0.79%。消息层面，截至01时53分，《受药物安全问题报道冲击，Morphosys称诺华制药收购仍将按计划进行》资讯为影响Morphosys的重要信息。截至发稿，Morphosys美股盘前下跌2.38%，诺华制药美股盘前上涨了0.63%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300153457a574f3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300153457a574f3b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431594928","title":"受药物安全问题报道冲击，Morphosys(MOR.US)称诺华制药(NVS.US)收购仍将按计划进行","url":"https://stock-news.laohu8.com/highlight/detail?id=2431594928","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431594928?lang=zh_cn&edition=full","pubTime":"2024-04-29 20:21","pubTimestamp":1714393287,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，德国生物技术公司Morphosys股价下滑，受到一则关于其药物或具有安全风险的新闻报道影响，但Morphosys表示，诺华制药对其收购仍有望在今年上半年完成。Pelabresib被视为Morphosys公司最有前途的药物之一，也是诺华制药对该公司感兴趣的原因之一。Morphosys发言人补充道：“诺华的收购计划正在稳步推进。”诺华制药于今年2月达成协议，将以27亿欧元的价格收购Morphosys公司。截至发稿，Morphosys美股盘前下跌2.38%，诺华制药美股盘前上涨了0.63%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1114925.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426253531","title":"诺华制药(NVS.US)对MorphoSys(MOR.US)发起收购要约 收购价68欧元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426253531","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2426253531?lang=zh_cn&edition=full","pubTime":"2024-04-11 19:32","pubTimestamp":1712835152,"startTime":"0","endTime":"0","summary":"诺华制药已经对德国癌症制药商MorphoSys发起了收购要约，拟以每股68欧元或总计27亿欧元的现金收购该公司所有已发行股票。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20240411/20240411193309_72568.png?x-oss-process=image/format,jpg/quality,Q_80","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240411/20240411193309_72568.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1101291.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2418153954","title":"德国监管机构批准诺华27亿欧元收购生物制药公司MorphoSys","url":"https://stock-news.laohu8.com/highlight/detail?id=2418153954","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2418153954?lang=zh_cn&edition=full","pubTime":"2024-03-12 20:46","pubTimestamp":1710247602,"startTime":"0","endTime":"0","summary":"德国反垄断机构联邦卡特尔局3月12日发布声明，批准瑞士制药巨头诺华收购德国生物技术公司MorphoSys的交易。2月5日，诺华宣布将以每股68欧元或总计27亿欧元现金收购MorphoSys。此次收购需满足惯例成交条件，包括收购要约中最低65%流通股的接受门槛以及监管部门的批准。根据声明，此次收购将进一步扩展和补充诺华在肿瘤学这一优先治疗领域的产品线，同时将加强诺华在血液学领域的全球布局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403122046427919b87a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403122046427919b87a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2409224388","title":"MorphoSys(MOR)盘前涨超5% 获诺华制药(NVS)以27亿欧元收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2409224388","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2409224388?lang=zh_cn&edition=full","pubTime":"2024-02-07 22:04","pubTimestamp":1707314683,"startTime":"0","endTime":"0","summary":"金吾财讯 | MorphoSys(MOR)美股盘前涨超5%，报17.1美元。消息面上，诺华制药(NVS)同意以27亿欧元收购MorphoSys，将这家德国制药商的癌症治疗药物纳入其产品线。交易已经获得了双方公司董事会的一致批准，预计于2024年上半年完成，完成后将把MorphoSys私有化。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/MzE4MDg0MTAxNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MzE4MDg0MTAxNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"272808","is_publish_highlight":false,"gpt_icon":0},{"id":"2409028192","title":"诺华制药拟斥资27亿欧元溢价六成收购MorphoSys 后者周一大涨56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2409028192","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2409028192?lang=zh_cn&edition=full","pubTime":"2024-02-07 01:23","pubTimestamp":1707240221,"startTime":"0","endTime":"0","summary":"诺华制药同意以27亿欧元(约合29亿美元)收购德国制药商morphosys，将其癌症治疗药物纳入其产品线。诺华制药将以每股68欧元的现金收购该公司，比该股2月2日在欧洲的收盘价高出61%。周一，MORphosys股价美股收盘上涨56%，报17.27美元。收购MorphoSys是诺华首席执行官Vas Narasimhan的最新举措，该公司近期在药品方面遭遇挫折。Narasimhan在并购方面的记录不佳，需要向投资者证明，在对业务进行大规模重组后，他仍能推动业务增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240207014547877599d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240207014547877599d5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2409228594","title":"Morphosys盘中异动 临近午盘急速下跌5.33%报16.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2409228594","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2409228594?lang=zh_cn&edition=full","pubTime":"2024-02-07 00:50","pubTimestamp":1707238225,"startTime":"0","endTime":"0","summary":"北京时间2024年02月07日00时50分，Morphosys股票出现波动，股价快速跳水5.33%。Morphosys股票所在的生物技术行业中，整体跌幅为1.07%。Morphosys公司简介：MorphoSys AG 是一家生物制药公司，致力于发现、开发和商业化治疗癌症和自身免疫性疾病患者的疗法。MorphoSys 正在推进自己的新候选药物管道，并创建了由合作伙伴在未满足医疗需求的不同领域开发的抗体。消息层面，截至00时50分，Morphosys股票正面舆情新闻比例20%。《MorphoSys飙涨56% 获诺华制药斥资27亿欧元收购》资讯为影响Morphosys的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402070050257a41f15c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402070050257a41f15c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2409408895","title":"诺华制药将以27亿欧元收购生物制药公司MorphoSys","url":"https://stock-news.laohu8.com/highlight/detail?id=2409408895","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2409408895?lang=zh_cn&edition=full","pubTime":"2024-02-06 21:03","pubTimestamp":1707224602,"startTime":"0","endTime":"0","summary":"2月6日消息，诺华制药宣布将以27亿欧元收购总部位于德国的生物制药公司MorphoSys，将MorphoSys的癌症治疗药物纳入其产品线。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240206210322790fa743&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240206210322790fa743&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2409472103","title":"MorphoSys(MOR.US)飙涨56% 获诺华制药(NVS.US)斥资27亿欧元收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2409472103","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2409472103?lang=zh_cn&edition=full","pubTime":"2024-02-06 20:37","pubTimestamp":1707223020,"startTime":"0","endTime":"0","summary":"智通财经获悉，诺华制药同意以27亿欧元收购MorphoSys，将这家德国制药商的癌症治疗药物纳入其产品线。周一，Morphosys股价美股收盘上涨56%，报17.27美元。收购MorphoSys是诺华首席执行官Vas Narasimhan的最新举措，该公司近期在药品方面遭遇挫折。MorphoSys是他此后最大的一笔交易。在周一宣布的另一项交易中，MorphoSys同意以2500万美元的价格将Monjuvi的全球版权出售给合作伙伴Incyte Corp.。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1069632.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2409795493","title":"诺华制药将以每股68欧元收购MorphoSys AG","url":"https://stock-news.laohu8.com/highlight/detail?id=2409795493","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2409795493?lang=zh_cn&edition=full","pubTime":"2024-02-06 09:09","pubTimestamp":1707181775,"startTime":"0","endTime":"0","summary":"诺华制药将以每股68欧元收购德国后期生物制药公司MorphoSys AG。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402060917278772a1df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402060917278772a1df&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2409949848","title":"诺华27亿欧元收购MorphoSys，Incyte从MorphoSys获CD19单抗全球权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2409949848","media":"医药魔方","top":-1,"share":"https://www.laohu8.com/m/news/2409949848?lang=zh_cn&edition=full","pubTime":"2024-02-06 08:24","pubTimestamp":1707179082,"startTime":"0","endTime":"0","summary":"2月5日，诺华宣布将以每股68欧元或总计27亿欧元现金收购MorphoSys AG。与此同时，Incyte在同日宣布已与MorphoSys签署了一项资产购买协议，Incyte获得了tafasitamab的全球独家开发和商业化权利，tafasitamab是一种人源化Fc修饰的CD19靶向免疫疗法。根据近日MorphoSys发布的新闻稿，tafasitamab在2023年美国地区的销售额约为9200万美元。2020年1月，Incyte又与Morphosys达成合作协议，支付后者7.5亿美元预付款+1.5亿美元股权投资+11亿美元里程碑金额。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240206084121816f6a94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240206084121816f6a94&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2409458057","title":"BUZZ-路透报道诺华正在进行收购谈判后，MorphoSys 大涨 50","url":"https://stock-news.laohu8.com/highlight/detail?id=2409458057","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2409458057?lang=zh_cn&edition=full","pubTime":"2024-02-06 01:53","pubTimestamp":1707155631,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    2月5日 - ** 据报道，制药商诺华（Novartis）  正在就收购这家药物开发商进行深入谈判。** MOR股价最高升至16.97美元，创下2021年7月以来的最高水平** 路透（(link)）援引两名知情人士的话报道说，诺华战胜了竞争对手Incyte公司  ，开始与MorphoSys公司进行收购谈判。** MorphoSys开发抗致命癌症药物** 随着本交易日的走势，在美国上市的公司股价在过去一年中上涨了约 230","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2408634196","title":"Morphosys盘中异动 早盘大幅拉升5.33%报11.07美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2408634196","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2408634196?lang=zh_cn&edition=full","pubTime":"2024-02-01 22:35","pubTimestamp":1706798131,"startTime":"0","endTime":"0","summary":"北京时间2024年02月01日22时35分，Morphosys股票出现异动，股价大幅拉升5.33%。截至发稿，该股报11.07美元/股，成交量3.9234万股，换手率0.03%，振幅1.71%。Morphosys股票所在的生物技术行业中，整体跌幅为0.23%。Morphosys公司简介：MorphoSys AG 是一家生物制药公司，致力于发现、开发和商业化治疗癌症和自身免疫性疾病患者的疗法。MorphoSys 正在推进自己的新候选药物管道，并创建了由合作伙伴在未满足医疗需求的不同领域开发的抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024020122353187e6b2d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024020122353187e6b2d9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2407813631","title":"Morphosys盘中异动 股价大跌5.02%报10.94美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2407813631","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2407813631?lang=zh_cn&edition=full","pubTime":"2024-01-30 02:36","pubTimestamp":1706553360,"startTime":"0","endTime":"0","summary":"北京时间2024年01月30日02时36分，Morphosys股票出现波动，股价大幅下跌5.02%。截至发稿，该股报10.94美元/股，成交量74.0391万股，换手率0.49%，振幅5.56%。Morphosys股票所在的生物技术行业中，整体涨幅为0.47%。其相关个股中，Palisade Bio Inc、Neximmune Inc、Fibrogen Inc涨幅较大，Revelation Biosciences Inc、Palisade Bio Inc、Panbela Therapeutics Inc较为活跃，换手率分别为2339.18%、1328.94%、1152.85%，振幅较大的相关个股有Neximmune Inc、Revelation Biosciences Inc、Palisade Bio Inc，振幅分别为112.34%、107.95%、106.90%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202401300236007a3f55f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202401300236007a3f55f3&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2406790316","title":"Morphosys盘中异动 早盘股价大涨5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2406790316","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2406790316?lang=zh_cn&edition=full","pubTime":"2024-01-27 00:04","pubTimestamp":1706285096,"startTime":"0","endTime":"0","summary":"北京时间2024年01月27日00时04分，Morphosys股票出现异动，股价快速拉升5.17%。截至发稿，该股报10.38美元/股，成交量12.9583万股，换手率0.09%，振幅1.67%。Morphosys股票所在的生物技术行业中，整体跌幅为0.05%。Morphosys公司简介：MorphoSys AG 是一家生物制药公司，致力于发现、开发和商业化治疗癌症和自身免疫性疾病患者的疗法。MorphoSys 正在推进自己的新候选药物管道，并创建了由合作伙伴在未满足医疗需求的不同领域开发的抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202401270004567a3ebf02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202401270004567a3ebf02&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2406953214","title":"Morphosys盘中异动 快速拉升5.01%报10.07美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2406953214","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2406953214?lang=zh_cn&edition=full","pubTime":"2024-01-25 22:30","pubTimestamp":1706193047,"startTime":"0","endTime":"0","summary":"北京时间2024年01月25日22时30分，Morphosys股票出现波动，股价急速拉升5.01%。截至发稿，该股报10.07美元/股，成交量1.0636万股，换手率0.01%，振幅0.42%。Morphosys股票所在的生物技术行业中，整体涨幅为0.00%。Morphosys公司简介：MorphoSys AG 是一家生物制药公司，致力于发现、开发和商业化治疗癌症和自身免疫性疾病患者的疗法。MorphoSys 正在推进自己的新候选药物管道，并创建了由合作伙伴在未满足医疗需求的不同领域开发的抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240125223048790c2678&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240125223048790c2678&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2405413924","title":"Morphosys盘中异动 早盘急速拉升6.58%报9.72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2405413924","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2405413924?lang=zh_cn&edition=full","pubTime":"2024-01-24 22:32","pubTimestamp":1706106733,"startTime":"0","endTime":"0","summary":"北京时间2024年01月24日22时32分，Morphosys股票出现波动，股价大幅上涨6.58%。截至发稿，该股报9.72美元/股，成交量2.8605万股，换手率0.02%，振幅1.97%。Morphosys股票所在的生物技术行业中，整体涨幅为0.09%。Morphosys公司简介：MorphoSys AG 是一家生物制药公司，致力于发现、开发和商业化治疗癌症和自身免疫性疾病患者的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024012422321387e0416d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024012422321387e0416d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2404653584","title":"Morphosys盘中异动 股价大跌5.05%报10.43美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2404653584","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2404653584?lang=zh_cn&edition=full","pubTime":"2024-01-18 22:57","pubTimestamp":1705589834,"startTime":"0","endTime":"0","summary":"北京时间2024年01月18日22时57分，Morphosys股票出现波动，股价大幅下挫5.05%。截至发稿，该股报10.43美元/股，成交量20.0386万股，换手率0.13%，振幅5.19%。Morphosys股票所在的生物技术行业中，整体跌幅为0.75%。其相关个股中，Celularity Inc、Biocardia Inc C/Wts 06/08/2024、Apollomics Inc C/Wts 01/04/2028 涨幅较大，Kintara Therapeutics Inc、Transcode Therapeutics Inc、Zyversa Therapeutics Inc较为活跃，换手率分别为73.39%、52.91%、30.20%，振幅较大的相关个股有Celularity Inc、Pasithea Therapeutics Corp C/Wts 12/08/2026 、Azitra Inc，振幅分别为28.68%、20.63%、19.37%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024011822571487e664fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024011822571487e664fe&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.morphosys.com","stockEarnings":[{"period":"1week","weight":0.0061},{"period":"1month","weight":-0.0011},{"period":"3month","weight":0.0496},{"period":"6month","weight":1.3684},{"period":"1year","weight":2.2609},{"period":"ytd","weight":0.8182}],"compareEarnings":[{"period":"1week","weight":0.0187},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0392},{"period":"6month","weight":0.1821},{"period":"1year","weight":0.2638},{"period":"ytd","weight":0.0958}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"MorphoSys AG成立于1998年3月3日，是一家后期生物制药公司，致力于为患有严重疾病的患者开发创新和差异化疗法。基于其在治疗性抗体发现，发电和工程领域的专有技术平台和领先地位，该公司与其合作伙伴一起参与了100多种治疗性产品的开发。他们广泛的管线跨越两个业务部分：专有开发以及合作发现，该公司根据合作伙伴确定的目标为其制药和生物技术行业的合作伙伴生成候选产品。该公司目前在临床开发中有28种产品候选产品，包括最先进的专利产品候选产品MOR208，用于治疗复发或难治性弥漫大B细胞淋巴瘤。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.045203},{"month":2,"riseRate":0.166667,"avgChangeRate":0.01596},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.06954},{"month":4,"riseRate":0.666667,"avgChangeRate":0.051271},{"month":5,"riseRate":0.714286,"avgChangeRate":0.066826},{"month":6,"riseRate":0.5,"avgChangeRate":0.004548},{"month":7,"riseRate":0.666667,"avgChangeRate":0.032087},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.046357},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.05312},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.033728},{"month":11,"riseRate":0.5,"avgChangeRate":0.014564},{"month":12,"riseRate":0.5,"avgChangeRate":0.047817}],"exchange":"NASDAQ","name":"Morphosys AG","nameEN":"Morphosys AG"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Morphosys AG(MOR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Morphosys AG(MOR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Morphosys AG,MOR,Morphosys AG股票,Morphosys AG股票老虎,Morphosys AG股票老虎国际,Morphosys AG行情,Morphosys AG股票行情,Morphosys AG股价,Morphosys AG股市,Morphosys AG股票价格,Morphosys AG股票交易,Morphosys AG股票购买,Morphosys AG股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Morphosys AG(MOR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Morphosys AG(MOR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}